(19)
(11) EP 3 924 360 A1

(12)

(43) Date of publication:
22.12.2021 Bulletin 2021/51

(21) Application number: 20712111.2

(22) Date of filing: 13.02.2020
(51) International Patent Classification (IPC): 
C07H 19/14(2006.01)
A61P 35/00(2006.01)
 A61K 31/706(2006.01)
A61P 35/02(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/519; A61K 45/06; A61P 35/00; A61P 35/02; C07H 19/14
 
C-Sets:
A61K 31/519, A61K 2300/00;
(86) International application number:
PCT/US2020/018185
(87) International publication number:
WO 2020/168125 (20.08.2020 Gazette 2020/34)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 13.02.2019 US 201962805175 P
14.02.2019 US 201962805726 P

(71) Applicant: Prelude Therapeutics, Incorporated
Wilmington, DE 19803 (US)

(72) Inventors:
  • LIN, Hong
    Exton, PA 19341 (US)
  • LI, Qun
    Newark, DE 19702 (US)
  • ANDRES, Mark
    West Lafayette, IN 47906 (US)
  • ZHANG, Huaping
    Newark, DE 19702 (US)

(74) Representative: Abthorpe, Mark et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)

   


(54) SELECTIVE INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)